Target type: biologicalprocess
The formation of bone or of a bony substance, or the conversion of fibrous tissue or of cartilage into bone, involved in the progression of the skeleton from its formation to its mature state. [GOC:dph, GOC:mah, GOC:mtg_mpo]
Ossification, also known as bone formation, is a complex biological process that involves the development and growth of bone tissue. It begins during fetal development and continues throughout life, albeit at a slower pace after puberty. There are two primary types of ossification: intramembranous ossification and endochondral ossification.
**Intramembranous Ossification**
This process occurs directly within mesenchymal connective tissue, which is a type of embryonic tissue. It is responsible for forming flat bones, such as the bones of the skull, clavicle, and parts of the mandible. The process involves the following steps:
1. **Mesenchymal cells differentiate into osteoblasts:** Osteoblasts are specialized cells that produce the organic matrix of bone, called osteoid.
2. **Osteoid production and mineralization:** Osteoblasts deposit osteoid, which then becomes mineralized by the deposition of calcium salts. This forms bony spicules.
3. **Formation of trabeculae:** The bony spicules fuse together to form a network of trabeculae, which are interconnected bony plates.
4. **Development of periosteum:** A periosteum, a fibrous membrane that surrounds the bone, develops.
**Endochondral Ossification**
This process begins with a hyaline cartilage model, which is then replaced by bone tissue. It is responsible for forming most bones in the body, including long bones. The process involves the following steps:
1. **Formation of a cartilage model:** Mesenchymal cells condense and differentiate into chondroblasts, which produce hyaline cartilage.
2. **Chondrocyte growth and proliferation:** Chondrocytes within the cartilage model proliferate and enlarge.
3. **Calcification of the cartilage matrix:** The cartilage matrix begins to calcify, trapping chondrocytes and leading to their death.
4. **Invasion of blood vessels and osteoblasts:** Blood vessels invade the calcified cartilage, bringing with them osteoblasts.
5. **Formation of primary ossification center:** Osteoblasts lay down bone tissue on the calcified cartilage matrix, forming a primary ossification center.
6. **Secondary ossification centers:** In long bones, secondary ossification centers form in the epiphyses (ends of the bone).
7. **Formation of epiphyseal plate:** A layer of cartilage, called the epiphyseal plate, remains between the primary and secondary ossification centers. This plate is responsible for longitudinal bone growth.
8. **Bone remodeling:** Once the bone has reached its full size, the epiphyseal plate closes and bone remodeling continues throughout life to maintain bone strength and repair damage.
**Factors Affecting Ossification**
Several factors can influence the process of ossification, including:
* **Genetics:** Genes play a crucial role in determining bone growth and development.
* **Hormones:** Hormones like growth hormone, thyroid hormone, and sex hormones are essential for bone growth and maturation.
* **Nutrition:** Adequate intake of calcium, vitamin D, and other nutrients is vital for bone formation.
* **Mechanical stress:** Physical activity and weight-bearing exercise stimulate bone growth and density.
**Bone Maturation and Remodeling**
Bone growth and maturation continue until adulthood, when the epiphyseal plates close. After puberty, the skeleton reaches its peak bone mass. However, bone remodeling continues throughout life.
* **Bone resorption:** Osteoclasts, specialized cells that break down bone tissue, are responsible for resorption.
* **Bone deposition:** Osteoblasts, the bone-building cells, are responsible for deposition.
These processes are constantly balancing to maintain bone strength and density, adapting to changing needs and stresses.
'"
Protein | Definition | Taxonomy |
---|---|---|
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | A 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q15125] | Homo sapiens (human) |
Transforming protein RhoA | A GTP-binding protein RhoA that is encoded in the genome of human. [PRO:CNA, UniProtKB:P61586] | Homo sapiens (human) |
Ryanodine receptor 1 | A ryanodine receptor 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P21817] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
buflomedil | buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure | aromatic ketone | |
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
nafoxidine | Nafoxidine: An estrogen antagonist that has been used in the treatment of breast cancer. | benzenes; naphthalenes; ring assembly | |
nevirapine | nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. | cyclopropanes; dipyridodiazepine | antiviral drug; HIV-1 reverse transcriptase inhibitor |
raloxifene | raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively. | 1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols | bone density conservation agent; estrogen antagonist; estrogen receptor modulator |
trifluoperazine | N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines | antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug | |
trifluperidol | Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621) | aromatic ketone | |
corticosterone | 11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone | human metabolite; mouse metabolite | |
triparanol | Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts. | stilbenoid | anticoronaviral agent |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
opipramol | Opipramol: A tricyclic antidepressant with actions similar to AMITRIPTYLINE. | dibenzoazepine | |
jervine | jervine: teratogen from Veratrum grandiflorum; RN given refers to parent cpd(3beta,23beta)-isomer; structure | piperidines | |
naftifine | naftifine : A tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections. naftifine: allylamine der; RN given refers to unlabeled parent cpd | allylamine antifungal drug; naphthalenes; tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor; sterol biosynthesis inhibitor |
carbizocaine | |||
fenpropimorph | alkylbenzene | ||
chrysamine g | chrysamine G: structure given in first source; RN refers to disodium salt | ||
preclamol | |||
enclomiphene | Enclomiphene: The trans or (E)-isomer of clomiphene. | ||
zuclomiphene | Zuclomiphene: The cis or (Z)-isomer of clomiphene. | stilbenoid | |
terbinafine | acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor | |
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
bm 15766 | BM 15766: 7-dehydrocholesterol reductase antagonist | ||
bastadin 5 | |||
ne 100 | |||
sa 4503 | |||
bastadin 4 | |||
ccg-203971 |